

Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu 104th IAMM EQAS Microbiology: Bacteriology/ Serology Email: eqas@cmcvellore.ac.in Phone: 0416-2282588

NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

MARCH 2020

104th EQAS EVALUATION REPORT

MEMBER ID: Z 0 9

Marks Obtained: 70.5 /7396.6%)

MARCH 2020 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation. Provide the Impression or probable organism seen (AS ASKED)

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

Exercise Number	Question	Expected Report	Eva	Evaluation	
SM1	Please carry out a Gram stain on the given fixed smear prepared	Presence of host cells & debris (1 mark): Occasional pus cells, Many epithelial cells.	•	0.5	-
	of a 63-year old diabetic lady with a history of mild dysuria	in pairs, chains, groups. Many Gram negative bacilli (slender and thick). Many Gram positive bacilli, Moderate oval budding yeast like organisms.	1.5	2	2.5
	and increased frequency for 2	B B B B B B B)
	days.	Impression/comment (1 mark): Improperly collected specimen. Suggest repeat appropriately collected mid-stream clean catch specimen for culture.	ယ	3.5	4
SM2	Please carry out a Gram stain on	Presence of host cells & debris (1mark): Many pus cells.	0	0.5	1
	from an EXUDATE specimen of	Description of Organism/s (2 marks): Many Gram positive spherical cocci		•	2.5
	a 23-year old man presenting	in pairs and chains.	1.5	2	
	with an exudative lesion on the right leg associated with high	Possible organism (1 mark): Streptococcus species (Probably S. pyogenes)	သ	3.5	(2)
	for 2 days.				

SM3 Please carry out a Gram stain on the given fixed smear prepared from an ENDOTRACHEAL ASPIRATE specimen of a 69-year old gentleman admitted in the ICU with worsening saturation. Presence of host cells & debris (1 mark): Many pus cells. Description of Organism/s (2 marks): Many Gram negative cocco-bacilli 1.5 2 2.5 2.5 3 3.5 4 4
ve cocco-bacilli acter spp 1.5 2 3 3.5
ve cocco-bacilli acter spp 1.5 2 3 3.5
3.5
5
2.5

MARCH 2020 / BACTERIOLOGY CULTURE:

techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given Question: A freeze-dried (lyophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate

Please refer the attached evaluation format for details on the criteria for evaluation.

below.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated in the evaluation report below.

CU1: Isolated from a FECES specimen of a 26year old gentleman with a 2-day history of diarrhea and vomiting associated with abdominal pain. FINAL INDENTIFICATION: Non-agglutinating Vibrio cholerae (Non 01- Non 0139)

	FINALIGENTIFCATION	(Minimum 3 key characteristics)	findings enabling final identification	Salient culture and biochemical	Microscopy (Gram stain + Motility)		Identification details	
				<	<		Reported	
	reported	Serotype incorrectly					Not reported	
- 200	Dage 2 of 6	0 0.5 1 (1.5) 2		1 3 3	(0 0.5 (1)	Evaluation (1 marrow)	Timbion (7 marks)

Susceptibility report		EXPECTED REPORT	REPORT	PARTICIPANT REPORT	T REPORT	MARK	TYPE OF ERROR
H	Zone size (mm)	MIC (μg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Ampicillin	≥17	-≤8	Susceptible	<		-1 0 1 2	mE/ ME/ VME
Tetracycline	≥15	<u>4</u>	Susceptible	•		-1 0 12	mE/ ME/ VME
Co-trimoxazole	≥16	≤2-38	Susceptible	<		-1 0 1(2)	mE/ ME/ VME
Cefotaxmine	≥26	Δ	Susceptible	<		-1 0 1(2)	mE/ ME/ VME
Ciprofloxacin	≥21		Susceptible	<		-1 0 1(2)	mE/ ME/ VME

	-
	()
	_
	N
	:-
	460
	1
	70
	=
	0
	22
	-
	•
	7
	2
	-
	∹.
	0
	=
	=
	_
	20
	100
	$\overline{}$
	-
	$\overline{}$
	\sim
	$\overline{}$
	Z
	-
	1
	10
	6 2
- 1	
	Ĭ.
	CD.
	3
	=.
	0
	=
	-
	0
	-
	. 7
	23
	100
	w
	7.
	OI
	•
	-
	30
	2
	-
	0
	_
	0
	-
	-
17.2	JU
	ï
	ř
	'nt
	intl
	intle
	ntlen
	ntlem
	ntlema
	ntlema
	ntleman
	entleman v
	intleman w
	ntleman wi
	entleman wit
	intleman with
	intleman with
	intleman with
	entleman with h
	intleman with he
	entleman with her
	entleman with hen
	entleman with hem
	entleman with hemin
- W	entleman with hemip
	intleman with hemipl
	intleman with hemiple
	intleman with hemiples
	intleman with hemiplegi
•	entleman with hemiplegia
	entleman with hemiplegia
•	entleman with hemiplegia
• (entleman with hemiplegia or
. (intleman with hemiplegia on
• (intleman with hemiplegia on
•	entleman with hemiplegia on a
	entleman with hemiplegia on a
	entleman with hemiplegia on a l
	entleman with hemiplegia on a lo
• (entleman with hemiplegia on a lon
• (intleman with hemiplegia on a long
	intleman with hemiplegia on a long
•	entleman with hemiplegia on a long-
	CU2: Isolated from a URINE specimen of a 35year old gentleman with hemiplegia on a long-t
	intleman with hemiplegia on a long-te
	intleman with hemiplegia on a long-ter
• (intleman with hemiplegia on a long-terr
	intleman with hemiplegia on a long-term
	intleman with hemiplegia on a long-term
	intleman with hemiplegia on a long-term u
	intleman with hemiplegia on a long-term u
	intleman with hemiplegia on a long-term ur
	ntleman with hemiplegia on a long-term uri
	intleman with hemiplegia on a long-term urin
	entleman with hemiplegia on a long-term uring
	entleman with hemiplegia on a long-term urina
	entleman with hemiplegia on a long-term urinar
	intleman with hemiplegia on a long-term urinary
	intleman with hemiplegia on a long-term urinary
	intleman with hemiplegia on a long-term urinary c
	entleman with hemiplegia on a long-term urinary ca
•	intleman with hemiplegia on a long-term urinary car
	intleman with hemiplegia on a long-term urinary cat
• (intleman with hemiplegia on a long-term urinary cath
	intleman with hemiplegia on a long-term urinary cathe
	ntleman with hemiplegia on a long-term urinary cathet
	intleman with hemiplegia on a long-term urinary cathete
	intleman with hemiplegia on a long-term urinary catheter
	intleman with hemiplegia on a long-term urinary catheter
	intleman with hemiplegia on a long-term urinary catheter
	intleman with hemiplegia on a long-term urinary catheter
	intleman with hemiplegia on a long-term urinary catheter
	intleman with hemiplegia on a long-term urinary catheter

FINAL IDENTIFICATION: Serfulla marcescens			
Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	•		0 0.5 ①
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	*		1 2 3 🕘
Final identification	<		0 0.5 1 1.5 (2

mE/ ME/ VIVIE	-1 0 1(2)		<	Susceptible	ᡌ	≥23	Meropenem
mE/ ME/ VME	-1 0 1(2)		<	Susceptible	≤0.5	≥21	Levofloxacin
				resistance			clavulanate
mE/ME/VME	-1 0 1(2)		<	Intrinsic	>32	6	Amoxicillin-
mE/ ME/ VME	-1 0 1(2)		<	Susceptible	≤2-38	≥16	Co-trimoxazole
	NOT EVALUATED	LON		Caution use	4	18-20	Cefpodoxime ~
Error	8 marks	Incorrect	Correct		MIC (μg/ml)	Zone size (mm)	,
TYPE OF ERROR	MARK	NT REPORT	PARTICIPANT REPORT	ORT	EXPECTED REPORT	EX	Susceptibility report

CU3: Isolated from an EXUDATE specimen from a 22year old lady with a history of extensive burns to her right forearm.

FINAL IDENTIFICATION: Staphylococcus aureus (MRSA)

			Final identification
		<	
0 05 115 3			Identification (Minimum 3 key characteristics)
1 2 3(4)		<	Salient culture and biochemical findings enabling final
)			Microscopy
(•	Microscopy (Gram stain + Motility)
0 0.5(1)		•	
			Identification details
Evaluation (7 marks)	Not reported	Reported	

						ļ	Lillezolia
	4			Susceptione	4	>21	I :maralid
	-1 0 1		<	Guscontible			
mE/ ME/ VME			1	Susception	≤0.5	≥21	Clindamycin
IIIE/ INTE/ ATATE	-1 0 1@		<	Succentible	1		
TO ME / VMI				Susceptione	≤2-38	≥16	Co-trimoxazole
mE/ ME/ VIVIE	$-1 \ 0 \ 1(2)$	V	~	2			•
				Susceptible	≤0.5	≥23	Erythromycin ~
mE/ ME/ VME	-1 0 1(2)			2			
				Resistant	\%	≤21	Cefoxitin
mE/ ME/ VME	-1 0 1(2)		~		(µg/ml)	(mm)	
				Interpretation	MIC	Zone size	report
Error	10 marks	Incorrect	Correct	REFORE	EXPECTED REFORE		Susceptibility
TYPE OF EKKOK	MARK	IPANT REPORT	PARTICIPANT	DEBODT			
Odda do							

MARCH 2020 / SEROLOGY

Peer group (n) = 320Test method employed for detection C-reactive protein (CRP) at your lab: Turbidimetry

Please refer the attached evaluation format for details on the criteria for evaluation

SE3	SE2	SE1	P
CRP	CRP	CRP	Parameter
Positive	Negative	Positive	Your Result
241.8	2.7	27.0	Your Value (mg/L)
Positive	Negative	Positive	Intended Result
10.8659	2.1770	36.7014	Robust Mean
2.9648	1.4239	8.8178	Robust SD
0.22 to 241.8	0.0 to 39.65	1 to 312	Range (mg/L)
77.6	0.4	-1.1	Z & Z' score
2	2	2	Max Marks
1	2	2	Your Score

MARCH 2020 / SEROLOGY

Test method employed for detection Rheumatoid Factor (RF) at your lab: Turbidimetry Peer group (n) = 237

Please refer the attached evaluation format for details on the criteria for evaluation

SE3	SE2	SE1	
RF	RF	RF	Parameter
Positive	Negative	Negative	Your Result
268.8	7.4	4.6	Your Value (IU/mL)
Positive	Negative	Negative	Intended Result
45.2702	6.8716	11.5177	Robust Mean
10.2638	4.9366	5.3985	Robust SD
0.0 to 268.8	-2.70 to 389.96	0.0 to 230	Range (IU/mL)
21.8	0.1	-1.3	Z & Z' score
2	2	2	Max Marks
1	2	2	Your Score

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID:

1aximum marks = 73	Maximum 1	. 4	4	4	17	7	17	_	•	
96.6%	70.5	. 2	4	4	17	15	16.5	4	4	4
									MINIO	TTATC
btained	Marks obtained	SIE3	SE2	SE1	CU3	CU2	CUI	SM3	SM2	QM1

Scientific Co-ordinator Dr. Rani Diana Sahni Sun sumbt

Report Dispatch Date: 15.09.2020

Quality Manager Dr. John A Jude Prakash

Dr. V. Balaji
PT Co-ordinator

******************* End of Report **********

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID:

narks = 7	Maximum marks = 73	4	4	4	17	15	17	4	A	
96.6%	70.5	. 2	4	4	17	15	16.5	4	4	4
							A CONTRACTOR OF THE PROPERTY O	CALLO	DIVIE	LIME
otained	Marks obtained	SE3	SE2	SE1	CU3	CU2	CU1	SM3	SM2	CM1

Hammer amor

Scientific Co-ordinator Dr. Rani Diana Sahni

Report Dispatch Date: 15.09.2020

Quality Manager Dr. John A Jude Prakash

Dr. V. Balaji
PT Co-ordinator

****************** End of Report ***********